BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Datadog, Berkshire Hathaway Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street jumped in upbeat trading on Monday, on a greater chance of presidential candidate Donald Trump winning a second term after surviving an assassination attempt, while interest-rate cut hopes also aided market sentiment.

BUZZ-U.S. STOCKS ON THE MOVE-Health insurance firms, Super Micro, Datadog Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Dow hit a record high in Wall Street's upbeat trading on Monday, on a greater chance of presidential candidate Donald Trump winning a second term after surviving an assassination attempt, while interest-rate cut hopes also aided sentiment.

BUZZ-Health insurance stocks gain as odds of Trump victory rise after shooting ** Shares of health insurers rise between 2.85% and 1.87% in premarket trading ** Humana HUM.N rises 2.85% to $393.10, UnitedHealth UNH.N gains 2.39% to $523.75, CVS CVS.N up 1.86% to $60.10, and Cigna CI.N up 1.87% to $341.06 ** After the events of the weekend, investors appear to believe that a Trump victory could be more likely in the November election, says Morningstar analyst Julie Utterback ** Former U.S.

Chuck Close's estate settles lawsuit against Cigna over medical bills By Jonathan Stempel NEW YORK, July 12 (Reuters) - The estate of Chuck Close, the artist known for massive photorealist portraits of himself and others, settled a lawsuit accusing Cigna CI.N of failing to pay hundreds of thousands of dollars for needed medical care in the last years of his life.

BUZZ-CVS Health, Cigna down after report FTC to sue PBMs over insulin prices ** Shares of health insurers fall; CVS Health CVS.N down ~1% at $57.05 and Cigna CI.N slips 0.8% to $325.88 ** The U.S. Federal Trade Commission (FTC) plans to sue pharmacy-benefit managers (PBMs) CVS Health, Cigna and UnitedHealth UNH.N , a source familiar with the matter told Reuters ** The FTC is suing the companies over their tactics for negotiating prices for drugs, including insulin - source ** The FTC is also loo

UPDATE 5-US FTC to sue drug middlemen over insulin prices, source says Adds Novo declining comment, background on insulin By Jody Godoy and Mariam Sunny July 10 (Reuters) - The U.S. Federal Trade Commission is planning to sue UnitedHealth UNH.N , Cigna CI.N and CVS Health CVS.N over their tactics as middlemen in negotiating prices for drugs including insulin, a person familiar with the matter s aid on Wednesday.

US FTC to sue drug middlemen over insulin prices, WSJ reports July 10 (Reuters) - The U.S. Federal Trade Commission is planning to sue UnitedHealth UNH.N , Cigna CI.N and CVS Health CVS.N , the three largest pharmacy-benefit managers, over their tactics for negotiating prices for drugs including insulin, the Wall Street Journal reported on Wednesday, citing a person familiar with the matter.

BRIEF-FTC To Sue Unitedhealth Group, Cigna Group And CVS Health Over Insulin Prices- WSJ July 10 (Reuters) - FTC TO SUE UNITEDHEALTH GROUP’S OPTUMRX, CIGNA GROUP’S EXPRESS SCRIPTS AND CVS HEALTH’S CAREMARK OVER INSULIN PRICES- WSJ Source text : https://tinyurl.com/2cap4863 Further company coverage: CI.N

UPDATE 2-Middlemen have outsized influence on US drug prices, FTC says Adds UnitedHealth comment in paragraph 6 By Ahmed Aboulenein and Jody Godoy WASHINGTON, July 9 (Reuters) - The consolidation of pharmacies and health insurance companies through years of dealmaking has led to a handful of pharmacy benefit managers exercising outsized influence over prescription drug prices, the U.S.

BUZZ-PBMs slip after FTC indicates outsized influence of middlemen on US drug prices ** Shares of pharmacy benefit managers slip after the U.S. Federal Trade Commission says consolidation of pharmacies and health insurance companies through years of deal making has led to a handful of pharmacy benefit managers exercising outsized influence over prescription drug prices ** Shares of CVS CVS.N fall 1%, Humana HUM.N down 1.2% while UnitedHealth UNH.N marginally down ** Pharmacy benefit managers, or

EXPLAINER-Why are US pharmacy benefit managers under fire? By Ahmed Aboulenein WASHINGTON, July 9 (Reuters) - The U.S. Federal Trade Commission said on Tuesday in an interim report on its investigation into pharmacy benefit managers that healthcare consolidation has given the companies outsized influence over prescription drug prices that could warrant regulation.

Middlemen have outsized influence on US drug prices due to market consolidation, FTC says By Ahmed Aboulenein and Jody Godoy WASHINGTON, July 9 (Reuters) - The consolidation of pharmacies and health insurance companies through years of deal making has led to a handful of pharmacy benefit managers exercising outsized influence over prescription drug prices, the U.S.

U.S. RESEARCH ROUNDUP-Campbell Soup, Tesla, Walgreens June 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Campbell Soup, Tesla and Walgreens, on Wednesday. HIGHLIGHTS * Campbell Soup Co CPB.N : JP Morgan raises to overweight from neutral * Kratos Defense and Security Solutions KTOS.O : BTIG initiates coverage with Neutral rating * Rocket Lab USA Inc RKLB.O : BTIG initiates coverage with Neutral rating * Tesla Inc

UPDATE 1-Cigna's medical use trends in line with projections for 2023, 2024 -GS conference Adds details from the conference call throughout By Amina Niasse and Pratik Jain NEW YORK, June 11 (Reuters) - Health insurer Cigna's CI.N medical use trends across its portfolio were in line with its expectations for 2023 and 2024, CFO Brian Evanko said on Tuesday, citing the company's lack of Medicaid management.

UnitedHealth hack impacted outpatient claims for Cigna - GS conference NEW YORK, June 11 (Reuters) - Cigna's CFO Brian Evanko said the company's "outpatient dynamic" was impacted by the Change Healthcare hack which disrupted claims during the first quarter of 2024. The February ransomware attack on the largest U.S. insurer stole a "substantial portion" of personal data from American patients and disrupted provider payments.

FOCUS-AbbVie's tight grip on Humira market raises concerns about biosimilars By Patrick Wingrove June 7 (Reuters) - AbbVie’s ABBV.N top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for prescription biosimilars can survive in its current form, drug pricing experts and analysts say.

U.S. RESEARCH ROUNDUP-Elevance Health, Wesco International, WW Grainger May 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies including Elevance Health, Wesco International and WW Grainger, on Thursday. HIGHLIGHTS * Cigna Group CI.N : JP Morgan raises target price to $435 from $432 * Elevance Health Inc ELV.N : JP Morgan raises target price to $631 from $628 * Uipath Inc PATH.N : TD Cowen cuts to hold from buy * Wesco Internati

U.S. RESEARCH ROUNDUP-AMC Networks, Permian Resources, Vital Energy May 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AMC Networks, Permian Resources and Vital Energy, on Monday. HIGHLIGHTS * AMC Networks AMCX.O : Moffettnathanson cuts target price by $1 to $13 * Celanese Corp CE.N : Jefferies raises target price to $170 from $155 * Permian Resources Corp PR.N : Gerdes Energy Research raises to buy from neutral

CORRECTED-UPDATE 2-Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates Corrects in paragraph 6 to say Cigna and Optum are covering two or three Humira biosimilars By Steven Scheer JERUSALEM, May 8 (Reuters) - Teva Pharmaceutical Industries TEVA.TA said it was set to launch its long awaited biosimilar of AbbVie's ABBV.N blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024. The drugmaker also said late-stage results

U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Parker-Hannifin, Quaker Houghton May 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Berkshire Hathaway, Parker-Hannifin and Quaker Houghton, on Monday. HIGHLIGHTS * Berkshire Hathaway BRKa.N : KBW raises target price to $660,000 from $645,000 * Essex Property Trust Inc ESS.N : Piper Sandler raises target price to $315 from $291 * Parker-Hannifin Corp PH.N : Jefferies cuts